Dexmedetomidine pharmacokinetics in pediatric intensive care - a pooled analysis

被引:131
|
作者
Potts, Amanda L. [1 ]
Anderson, Brian J. [1 ]
Warman, Guy R. [1 ]
Lerman, Jerrold [2 ,3 ]
Diaz, Susan M. [4 ,5 ]
Vilo, Sanna [6 ]
机构
[1] Univ Auckland, Dept Anaesthesiol, Auckland 1, New Zealand
[2] SUNY Buffalo, Women & Childrens Hosp Buffalo, Buffalo, NY 14260 USA
[3] Univ Rochester, Strong Mem Hosp, Rochester, NY 14642 USA
[4] Rady Childrens Hosp & Hlth Ctr, Albuquerque, NM USA
[5] Presbyterian Healthcare Serv, Albuquerque, NM USA
[6] Turku Univ Hosp, Dept Anaesthesiol Intens Care Emergency Care & Pa, FIN-20520 Turku, Finland
关键词
dexmedetomidine; pharmacokinetics; children; allometrics; DOSE DEXMEDETOMIDINE; CHILDREN; SEDATION; INFUSION; SIZE; PHARMACODYNAMICS; INFANTS; RAT; BUPIVACAINE; VOLUNTEERS;
D O I
10.1111/j.1460-9592.2009.03133.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
P>Background: Published dexmedetomidine pharmacokinetic studies in children are limited by participant numbers and restricted pathology. Pooling the available studies allows investigation of covariate effects. Methods: Data from four studies investigating dexmedetomidine pharmacokinetics after i.v. administration (n = 95) were combined to undertake a population pharmacokinetic analysis of dexmedetomidine time-concentration profiles (730 observations) using nonlinear mixed effects modeling (NONMEM). Estimates were standardized to a 70-kg adult using allometric size models. Results: Children had a mean age of 3.8 (median 3 years, range 1 week-14 years) and weight of 16.0 kg (median 13.3 kg, range 3.1-58.9 kg). Population parameter estimates (between subject variability) for a two-compartment model were clearance (CL) 42.1 (CV 30.9%) l center dot h-1 center dot 70 kg-1, central volume of distribution (V1) 56.3 (61.3%) l center dot 70 kg-1, inter-compartment clearance (Q) 78.3 (37.0%) l center dot h-1 center dot 70 kg-1 and peripheral volume of distribution (V2) 69.0 (47.0%) l center dot 70 kg-1. Clearance maturation with age was described using the Hill equation. Clearance increases from 18.2 l center dot h-1 center dot 70 kg-1 at birth in a term neonate to reach 84.5% of the mature value by 1 year of age. Children given infusion after cardiac surgery had 27% reduced clearance compared to a population given bolus dose. Simulation of published infusion rates that provide adequate sedation for intensive care patients found a target therapeutic concentration of between 0.4 and 0.8 mu g center dot l-1. Conclusions: The sedation target concentration is similar to that described for adults. Immature clearance in the first year of life and a higher clearance (when expressed as l center dot h-1 center dot kg-1) in small children dictate infusion rates that change with age. Extrapolation of dose from children given infusion in intensive care after cardiac surgery may not be applicable to those sedated for noninvasive procedures out of intensive care.
引用
收藏
页码:1119 / 1129
页数:11
相关论文
共 50 条
  • [1] Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: Preliminary study
    Diaz, Susan M.
    Rodarte, Alexander
    Foley, Jennifer
    Capparelli, Edmund V.
    PEDIATRIC CRITICAL CARE MEDICINE, 2007, 8 (05) : 419 - 424
  • [2] Use of dexmedetomidine in a Pediatric Intensive Care Unit
    Rapan, Kristine A.
    Lewin, John J.
    Lee, Carlton K.
    Veltri, Michael A.
    Easley, R. B.
    CRITICAL CARE MEDICINE, 2007, 35 (12) : A243 - A243
  • [3] Use of dexmedetomidine in the pediatric intensive care unit
    Buck, Marcia L.
    Willson, Douglas F.
    PHARMACOTHERAPY, 2008, 28 (01): : 51 - 57
  • [4] Pharmacokinetics of dexmedetomidine infusions for patients in the intensive care unit
    RM Venn
    MD Karol
    RM Grounds
    Critical Care, 5 (Suppl 1):
  • [5] KIDNEY INJURY AFTER PERCUTANEOUS AND POPULATION PHARMACOKINETICS (PK) OF DEXMEDETOMIDINE (DEX) IN PEDIATRIC INTENSIVE CARE
    Fiedler-Kelly, J.
    Ludwig, E.
    Stalker, D.
    ANESTHESIA AND ANALGESIA, 2012, 114
  • [6] An unintentional overdose of dexmedetomidine in the pediatric intensive care unit
    Sud, Payal
    Choi, Andrew
    Nogar, Joshua
    CLINICAL TOXICOLOGY, 2013, 51 (07) : 600 - 600
  • [7] Pharmacokinetics of levosimendan in pediatric intensive care unit
    Duflot, T.
    Pereira, T.
    Lecomte, J.
    Davril, E.
    Berthomieu, L.
    Imbert, L.
    Oualha, M.
    Lamoureux, F.
    Joram, N.
    Chenouard, A.
    Bourgoin, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 162 - 163
  • [8] Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care
    Venn, RM
    Karol, MD
    Grounds, RM
    BRITISH JOURNAL OF ANAESTHESIA, 2002, 88 (05) : 669 - 675
  • [9] Highly variable pharmacokinetics of dexmedetomidine during intensive care: A case report
    Iirola T.
    Laitio R.
    Kentala E.
    Aantaa R.
    Kurvinen J.-P.
    Scheinin M.
    Olkkola K.T.
    Journal of Medical Case Reports, 4 (1)
  • [10] DOBUTAMINE PHARMACOKINETICS IN PEDIATRIC INTENSIVE-CARE PATIENTS
    HABIB, DM
    PADBURY, JF
    PERKIN, RM
    ANAS, NG
    MARTINEZ, AM
    MINAGAR, C
    CLINICAL RESEARCH, 1989, 37 (01): : A176 - A176